ATC Group: C10AB08 Ciprofibrate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C10AB08 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C10 Lipid modifying agents
3 C10A Lipid modifying agents, plain
4 C10AB Fibrates
5 C10AB08 Ciprofibrate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.1 g

Active ingredients in C10AB08

Active Ingredient Description
Ciprofibrate

Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol.

Related product monographs

Title Information Source Document Type  
MODALIM Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Estonia (EE)

France (FR)

Israel (IL)

Mexico (MX)

Netherlands (NL)

Poland (PL)

Singapore (SG)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.